Lupin Shifts Its Focus To Complexity With Biosimilars And Specialty Plans On Horizon

As It Reports Highest Margins And US Revenues In Five Years

 
• By Urtė Fultinavičiūtė

While quarterly revenues show ups and downs in each region, Lupin is set on continued growth, with a touch of complexity and innovation – including shifting its thinking on the attractiveness of biosimilars.

Illustration of a person on a ladder. Concept of thinking outside of the box
(Shutterstock)

Just last year, over the course of a couple of quarterly updates, Lupin’s CEO Vinita Gupta said that the firm was taking a “cautious approach” on biosimilars and calling it a “difficult marketplace”. However, it seems that Lupin has changed its mind.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Products